TABLE 2.
Relative effect of RTV on plasma APV pharmacokinetics when coadministered with FPV or APVa
| Pharmacokinetic parameter | Ratio of GLS means (90% confidence interval)
|
Compound ratio FPV + RTV/FPV: APV + RT/APV | |
|---|---|---|---|
| APV + RTV/APV (n = 11) | FPV + RTV/ FPV (n = 15) | ||
| AUCτ,ss (μg · h/ml) | 3.16 (2.83-3.53) | 3.40 (3.09-3.75) | 1.08 (0.93-1.24) |
| Cmax,ss (μg · h/ml) | 1.27 (1.11-1.46) | 1.51 (1.34-1.70) | 1.19 (0.99-1.43) |
| Cτ,ss (μg/ml) | 10.73 (7.82-14.73) | 12.68 (9.67-16.64) | 1.18 (0.78-1.79) |
a
APV was used at 600 mg BID for 14 days. APV + RTV, APV at 600 mg BID and RTV at 100 mg BID for 14 days. FPV, 700 mg BID for 14 days. FPV + RTV, FPV 700 mg BID + RTV at 100 mg BID for 14 days. Each FPV oral film-coated 700-mg tablet is the molar equivalent of 600 mg APV.